EUCTR2020-004488-14-DK进行中（未招募）1 期
Bioavailability study of intranasal sufentanil/ketamine fixed combination in healthy volunteers
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •i) Healthy volunteers; male
- •ii) Age from 18 up to 55 years
- •iii) Non-smokers
- •iv) Body mass index (BMI) from 18.5 kg/m2 up to 30 kg/m2
- •v) Categorized as ASA Physical Status Class 1 or 2
- •vi) Clinically normal medical history, physical findings, vital signs, ECG and laboratory values as judged by the investigator at the time of the screening visit. A potential participant with measurements outside of the reference range for the population being studied may be included at the investigator´s discretion provided the finding is unlikely to introduce additional risk factors, jeopardize study integrity, or to interfere with the study assessments or procedures.
- •vii) The potential participant gives written informed consent for participation in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •i)Current or history of any clinically significant disease or disorder, which, in the opinion of the investigator, may put the potential participant at risk when participating in the study, or influence the potential participant’s ability to participate in the study or influence the study results.
- •ii.) Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the administration of investigational product that is likely to introduce additional risk factors, jeopardize study integrity, or to interfere with the study assessments or procedure
- •iii.) Mental illness
- •iv.) Opioid Risk Tool score of >3
- •v.) Pain Catastrophizing Scale score, total points >30
- •vi.) Hospital Anxiety and Depression Scale (HADS), points =11 for anxiety or =11 points for depression
- •vii.) Daily intake of analgesics
- •viii.) History of alcohol or drug abuse or use of illicit drugs Positive screen for drugs of abuse at screening or on admission to the Clinic prior to the administration of investigational product.
- •ix.) Use of prescription drugs within 14 days or over-the-counter drugs 24 hours (intranasal medication 48 hours) prior to the first dose of study medication, unless it is the opinion of the Investigator that the medication will not interfere with the study procedures or compromise participant
- •x.) Participants who have planned any scheduled invasive treatment or medical/surgical procedure during the study period
- •xi.) Participant showing abnormal nasal cavity/airway such as:
- •a. major septal deviation
- •b. evidence of previous nasal disease, surgery, and dependence of inhaled drug
- •c. current significant nasal congestion due to common cold
- •d. minimum air flow during each nasal passage
- •xii.) History or presence of allergy to the study drug or drugs of this class, or a history of drug or other allergy that, in the opinion of the investigator, contraindicates their participation
- •xiii.) Positive tests for HIV, hepatitis B and hepatitis C
- •xiv.) Positive COVID-19 test or clinical symptoms of COVID-19 (testing of participants will follow the health authorities’ guidelines and current guidelines for the Capital Region of Denmark)
- •xv.) Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days of signing the informed consent for this trial
- •xvi.) Blood donation within 4 weeks prior to the first dosing visit
研究者
相似试验
已完成
2 期
Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in ChildrenPainNCT01047241Danish University of Pharmaceutical Sciences50
进行中（未招募）
1 期
Pharmacological characteristics of intranasally given dexmedetomidinein paediatric patientsEUCTR2016-002880-33-FIniversity of Turku50
尚未招募
2 期
Effect of intranasal Ketamine in treatment of nephrolithiasisIRCT20180526039846N1Ahvaz University of Medical Sciences100
尚未招募
4 期
Comparison of the Effectiveness of Intranasal Ketamine, Intravenous Morphine Sulfate, and Intravenous Ketorolac in Reducing the Pain of the Renal Colic Patients in the Emergency Department of Shohadeye Ashayer Hospital of Khorramabad: A Randomized Controlled TrialIRCT20230718058838N1Khoram-Abad University of Medical Sciences99
进行中（未招募）
1 期
Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Departmentvaso-occlusive crisis due to sickle cell diseaseMedDRA version: 20.0Level: LLTClassification code: 10072397Term: Vaso-occlusive crisis Class: 10005329CTIS2023-504847-15-00Assistance Publique Hopitaux De Paris915